Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | President and CFO | August 16, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Pharma, Inc.
Report date August 16, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 336,529 |
Reported balance
After 2026-08-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-16 · Tax withholding · Disposed 22,781 · Balance 336,529 F1: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 41,194 shares of Common Stock underlying the Reporting Person's RSUs. F2: Includes 116 shares of the Issuer's Common Stock acquired by the Reporting Person on August 14, 2026 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 41,194 shares of Common Stock underlying the Reporting Person's RSUs.
F2: Includes 116 shares of the Issuer's Common Stock acquired by the Reporting Person on August 14, 2026 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 16, 2026 Filed Aug 18, 2026 22:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 22,781 | $79.86 | $1,819,290.66 |
DisclosureSEC source: 0001470831-26-000837 · wk-form4_1787090557.xml · nonDerivative · entry 1 Trimarchi Thomas · CIK 0002030813 · President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,529 F1 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 41,194 shares of Common Stock underlying the Reporting Person's RSUs. F2 · balance_after: Includes 116 shares of the Issuer's Common Stock acquired by the Reporting Person on August 14, 2026 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| May 18, 2026 Filed May 19, 2026 20:30 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 3,195 | $65.95 | $210,712.49 |
DisclosureSEC source: 0001470831-26-000473 · wk-form4_1779222603.xml · nonDerivative · entry 3 Trimarchi Thomas · CIK 0002030813 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 359,194 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F4 · price: Represents the weighted average sale price of the shares sold from $65.54 to $66.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| May 18, 2026 Filed May 19, 2026 20:30 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 10,456 | $64.82 | $677,706.69 |
DisclosureSEC source: 0001470831-26-000473 · wk-form4_1779222603.xml · nonDerivative · entry 2 Trimarchi Thomas · CIK 0002030813 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 362,389 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F3 · price: Represents the weighted average sale price of the shares sold from $64.34 to $65.33 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| May 16, 2026 Filed May 19, 2026 20:30 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 22,781 | $66.13 | $1,506,507.53 |
DisclosureSEC source: 0001470831-26-000473 · wk-form4_1779222603.xml · nonDerivative · entry 1 Trimarchi Thomas · CIK 0002030813 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 372,845 F1 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 41,193 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 20:33 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantCommon Stock | 59,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000304 · wk-form4_1774038836.xml · nonDerivative · entry 1 Trimarchi Thomas · CIK 0002030813 · President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 395,626 F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/16th of the underlying shares on May 16, 2026, and as to 1/16th of the underlying shares each quarter thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 23:36 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 200 | $75.38 | $15,076.00 |
DisclosureSEC source: 0001470831-26-000184 · wk-form4_1771457784.xml · nonDerivative · entry 3 Trimarchi Thomas · CIK 0002030813 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 336,585 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 23:36 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 13,400 | $74.71 | $1,001,071.12 |
DisclosureSEC source: 0001470831-26-000184 · wk-form4_1771457784.xml · nonDerivative · entry 2 Trimarchi Thomas · CIK 0002030813 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 336,785 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F3 · price: Represents the weighted average sale price of the shares sold from $74.30 to $75.19 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 23:36 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 18,819 | $75.25 | $1,416,129.75 |
DisclosureSEC source: 0001470831-26-000184 · wk-form4_1771457784.xml · nonDerivative · entry 1 Trimarchi Thomas · CIK 0002030813 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 350,185 F1 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 37,503 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 23:25 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 13,826 | $75.15 | $1,039,023.90 |
DisclosureSEC source: 0001470831-25-000420 · wk-form4_1765927541.xml · nonDerivative · entry 1 Trimarchi Thomas · CIK 0002030813 · President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 369,004 F1 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 25,000 shares of Common Stock underlying the Reporting Person's Restricted Stock Units. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 00:28 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 6,956 | $66.84 | $464,937.65 |
DisclosureSEC source: 0001470831-25-000351 · wk-form4_1763512137.xml · nonDerivative · entry 3 Trimarchi Thomas · CIK 0002030813 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 382,830 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F4 · price: Represents the weighted average sale price of the shares sold from $66.61 to $67.26 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 00:28 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 9,978 | $66.19 | $660,466.77 |
DisclosureSEC source: 0001470831-25-000351 · wk-form4_1763512137.xml · nonDerivative · entry 2 Trimarchi Thomas · CIK 0002030813 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 389,786 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F3 · price: Represents the weighted average sale price of the shares sold from $65.575 to $66.57 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| November 16, 2025 Filed Nov 19, 2025 00:28 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 21,317 | $66.39 | $1,415,235.63 |
DisclosureSEC source: 0001470831-25-000351 · wk-form4_1763512137.xml · nonDerivative · entry 1 Trimarchi Thomas · CIK 0002030813 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 399,764 F1 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 38,547 shares of Common Stock underlying the Reporting Person's Restricted Stock Units. Read SEC document |
| August 21, 2025 Filed Aug 22, 2025 20:58 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 42,237 | $49.48 | $2,090,081.05 |
DisclosureSEC source: 0000950170-25-111011 · ownership.xml · nonDerivative · entry 1 Trimarchi Thomas · CIK 0002030813 · President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 421,081 F1 · price: Represents the weighted average sale price of the shares sold from $49.08 to $49.77 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 23:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,973 | $50.94 | $100,512.31 |
DisclosureSEC source: 0000950170-25-110274 · ownership.xml · nonDerivative · entry 3 Trimarchi Thomas · CIK 0002030813 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 463,318 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F4 · price: Represents the weighted average sale price of the shares sold from $50.83 to $50.95 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 23:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 15,380 | $50.14 | $771,210.11 |
DisclosureSEC source: 0000950170-25-110274 · ownership.xml · nonDerivative · entry 2 Trimarchi Thomas · CIK 0002030813 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 465,291 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F3 · price: Represents the weighted average sale price of the shares sold from $49.76 to $50.75 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| August 16, 2025 Filed Aug 19, 2025 23:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 21,317 | $51.32 | $1,093,988.44 |
DisclosureSEC source: 0000950170-25-110274 · ownership.xml · nonDerivative · entry 1 Trimarchi Thomas · CIK 0002030813 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 480,671 F1 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 38,547 shares of Common Stock underlying the Reporting Person's Restricted Stock Units. Read SEC document |
| May 16, 2025 Filed May 20, 2025 21:07 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 21,317 | $33.84 | $721,367.28 |
DisclosureSEC source: 0000950170-25-075346 · ownership.xml · nonDerivative · entry 1 Trimarchi Thomas · CIK 0002030813 · President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 501,988 F1 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 38,545 shares of Common Stock underlying the Reporting Person's Restricted Stock Units. Read SEC document |
| March 19, 2025 Filed Mar 21, 2025 22:32 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantCommon Stock | 109,100 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-043403 · ownership.xml · nonDerivative · entry 1 Trimarchi Thomas · CIK 0002030813 · President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 523,305 F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/16th of the underlying shares on May 16, 2025, and as to 1/16th of the underlying shares each quarter thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 01:51 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 13,782 | $34.90 | $480,991.80 |
DisclosureSEC source: 0000950170-25-023632 · ownership.xml · nonDerivative · entry 1 Trimarchi Thomas · CIK 0002030813 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 414,205 F1 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax obligation in connection with the vesting of 32,431 shares of Common Stock underlying the Reporting Person's Restricted Stock Units. Read SEC document |
| December 10, 2024 Filed Dec 13, 2024 00:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-135982 · ownership.xml · nonDerivative · entry 1 Trimarchi Thomas · CIK 0002030813 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 427,987 F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest with respect to 1/2 of the underlying shares on December 12, 2025. Thereafter, the remaining underlying shares shall vest on December 12, 2026, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSU's have no expiration date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| November 16, 2024 Filed Nov 19, 2024 23:13 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 17,936 | $23.72 | $425,441.92 |
DisclosureSEC source: 0000950170-24-128903 · ownership.xml · nonDerivative · entry 1 Trimarchi Thomas · CIK 0002030813 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 377,987 F1 · shares: Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 32,432 shares of Common Stock underlying the Reporting Person's restricted stock units. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 22:24 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 17,936 | $24.40 | $437,638.40 |
DisclosureSEC source: 0000950170-24-099267 · ownership.xml · nonDerivative · entry 1 Trimarchi Thomas · CIK 0002030813 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 395,923 F1 · shares: Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 32,431 shares of Common Stock underlying the Reporting Person's restricted stock units. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 20:39 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 3,160 | $0.00 Strike: $24.87 | $0.00 |
DisclosureSEC source: 0000950170-24-094117 · ownership.xml · derivative · entry 2 Trimarchi Thomas · CIK 0002030813 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,160 Underlying: Common Stock · 3,160 shares Expires 2034-08-05 F3 · derivative.exercise_date: The stock option shall vest in 16 quarterly installments beginning on August 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 20:39 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantCommon Stock | 19,003 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-094117 · ownership.xml · nonDerivative · entry 1 Trimarchi Thomas · CIK 0002030813 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 413,859 F1 · kind: Grant of restricted stock units (RSUs) under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs shall vest in 16 quarterly installments beginning on August 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.